GEM SP - GEMACBIO
Latest Information Update: 09 Mar 2011
At a glance
- Originator GEMACBIO
- Developer GemacBio
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 18 Jul 2005 Phase-II clinical trials in Multiple sclerosis in France (unspecified route)